Gyre Therapeutics, Inc. completed its acquisition of Cullgen Inc. on 2026-05-04, according to the Form 8-K Gyre Therapeutics, Inc. filed with the SEC on 2026-05-04. The filing's Item 2.01 states no aggregate dollar price.
| Acquirer | Gyre Therapeutics, Inc. |
|---|---|
| Acquired | Cullgen Inc. |
| Completed | 2026-05-04 |
| Reported by | Gyre Therapeutics, Inc. (GYRE), the buyer |
| Filing | Form 8-K, filed 2026-05-04 |
Want the whole picture on Gyre Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Gyre Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Gyre Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
Agreement and Plan of Merger and Reorganization On May 4, 2026 (the "Closing Date"), Gyre Therapeutics, Inc., a Delaware corporation (the "Company" or "Gyre"), consummated the previously announced acquisition of Cullgen Inc., a Delaware corporation ("Cullgen"), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated March 2, 2026 (the "Merger Agreement"), by and among the Company, Helix Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub"), and Cullgen.
More from the filing
Pursuant to the Merger Agreement, Merger Sub merged with and into Cullgen, with Cullgen continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the "Merger").
The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.
Under the terms of the Merger Agreement, the Company acquired Cullgen in an all-stock transaction that valued Cullgen at approximately $300 million.
Quoted from Gyre Therapeutics, Inc.'s Form 8-K.
This is the only completed acquisition Gyre Therapeutics, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Gyre Therapeutics, Inc.Look up Gyre Therapeutics, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.